• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用改良的治疗-扩展方案治疗新生血管性年龄相关性黄斑变性的临床结果。

Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration.

机构信息

Ophthalmology, Hadassah Medical Center, Jerusalem, Israel.

Ophthalmology, Hadassah Medical Center, Jerusalem, Israel

出版信息

BMJ Open Ophthalmol. 2022 Dec;7(1). doi: 10.1136/bmjophth-2022-001180.

DOI:10.1136/bmjophth-2022-001180
PMID:37585239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9791424/
Abstract

AIM

To compare outcome between patients treated using a modified treat-and-extend (mT&E) protocol and patients treated using a conventional T&E protocol.

METHODS

A retrospective cohort study of two groups of treatment-naïve neovascular age-related macular degeneration patients within a single centre were evaluated. One group treated using the conventional T&E protocol, with visual acuity, dilated fundus examination (DFE) and optical coherence tomography (OCT) performed at each visit. The second group treated using the mT&E protocol in which visual acuity and DFE were performed only every three visits. The main outcome measures were time spent per clinical visit, visual and anatomical outcomes measured for 36 months.

RESULTS

The T&E and mT&E groups included 135 eyes in 116 patients and 119 eyes in 94 patients, respectively, with similar baseline characteristics. At 36 months, the number of injections administered (7.9±2.9 vs 8.1±2.3 injections, respectively; p=0.55), the percentage of eyes that gained ≥15 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (23% vs 25.2%, respectively; p=0.39) and the percentage of eyes that lost ≥15 ETDRS letters (21.5% vs 17.7%; p=0.43, respectively) were similar between the T&E and mT&E groups. However, waiting and contact time were reduced during the OCT-only visits compared with the full visits, with an average of 41 min saved per patient encounter.

CONCLUSIONS

Both protocols yielded similar visual and anatomical outcomes. However, the mT&E protocol reduced the number of full visits, with considerably less time spent at the clinic.

摘要

目的

比较使用改良的治疗-延伸(mT&E)方案和常规 T&E 方案治疗的患者的结局。

方法

对单中心内的两组未经治疗的新生血管性年龄相关性黄斑变性患者进行回顾性队列研究。一组采用常规 T&E 方案治疗,每次就诊时均进行视力、散瞳眼底检查(DFE)和光学相干断层扫描(OCT)检查。第二组采用 mT&E 方案治疗,仅每三次就诊时进行视力和 DFE 检查。主要观察指标为每次临床就诊所花费的时间、36 个月时测量的视力和解剖学结果。

结果

T&E 和 mT&E 组分别纳入 116 例患者的 135 只眼和 94 例患者的 119 只眼,两组患者的基线特征相似。36 个月时,注射次数(分别为 7.9±2.9 和 8.1±2.3 次;p=0.55)、视力提高≥15 个早期糖尿病视网膜病变治疗研究(ETDRS)字母的眼数(分别为 23%和 25.2%;p=0.39)以及视力下降≥15 个 ETDRS 字母的眼数(分别为 21.5%和 17.7%;p=0.43)在 T&E 和 mT&E 组之间相似。然而,与全访视相比,OCT 仅访视时的等待和接触时间减少,每位患者每次就诊可节省 41 分钟。

结论

两种方案均获得了相似的视力和解剖学结果。然而,mT&E 方案减少了全访视的次数,在诊所有效减少了时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/2492dcdfcb6a/bmjophth-2022-001180f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/2a253f91bc6a/bmjophth-2022-001180f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/c56bc6bb2b2c/bmjophth-2022-001180f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/2492dcdfcb6a/bmjophth-2022-001180f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/2a253f91bc6a/bmjophth-2022-001180f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/c56bc6bb2b2c/bmjophth-2022-001180f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d60/9791424/2492dcdfcb6a/bmjophth-2022-001180f03.jpg

相似文献

1
Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration.采用改良的治疗-扩展方案治疗新生血管性年龄相关性黄斑变性的临床结果。
BMJ Open Ophthalmol. 2022 Dec;7(1). doi: 10.1136/bmjophth-2022-001180.
2
Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.评价经治疗的新生血管性年龄相关性黄斑变性月 24 疗效和安全性的后巩膜放射治疗:MERLOT 随机临床试验。
JAMA Ophthalmol. 2020 Aug 1;138(8):835-842. doi: 10.1001/jamaophthalmol.2020.2309.
3
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.玻璃体内注射雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性的治疗并延长方案对比
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1671-1677. doi: 10.1007/s00417-019-04360-9. Epub 2019 May 29.
4
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.加拿大雷珠单抗治疗和延长分析试验在新生血管性年龄相关性黄斑变性患者中的应用:雷珠单抗治疗和延长分析试验随机研究的一年结果。
Ophthalmology. 2019 Jun;126(6):841-848. doi: 10.1016/j.ophtha.2019.01.013. Epub 2019 Jan 21.
5
Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?OCT 引导下渗出型年龄相关性黄斑变性再治疗是否需要散瞳眼底检查?
Ophthalmol Retina. 2020 Feb;4(2):141-147. doi: 10.1016/j.oret.2019.09.006. Epub 2019 Sep 18.
6
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.真实世界中抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的疗效和成本效果分析:真实世界研究的系统评价和荟萃分析。
Adv Ther. 2020 Jan;37(1):300-315. doi: 10.1007/s12325-019-01147-6. Epub 2019 Nov 14.
7
Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.接受雷珠单抗治疗的新生血管性年龄相关性黄斑变性的视力结果;按基线视力分层。
Clin Exp Ophthalmol. 2011 Jan;39(1):5-8. doi: 10.1111/j.1442-9071.2010.02424.x. Epub 2010 Dec 16.
8
Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.新生血管性年龄相关性黄斑变性中每月一次与按需治疗-扩展雷珠单抗治疗的黄斑萎缩:来自 TREX-AMD 试验的结果。
Ophthalmology. 2017 Feb;124(2):215-223. doi: 10.1016/j.ophtha.2016.10.002. Epub 2016 Nov 15.
9
Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review.加拿大视网膜诊所应用玻璃体内雷珠单抗治疗新生血管性年龄相关性黄斑变性的疗效:回顾性研究。
Can J Ophthalmol. 2010 Dec;45(6):590-5. doi: 10.3129/i10-082.
10
Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration.抗血管内皮生长因子治疗与年龄相关性黄斑变性新生血管 10 年的疗效观察。
Eye (Lond). 2020 Oct;34(10):1888-1896. doi: 10.1038/s41433-020-0764-9. Epub 2020 Jan 24.

引用本文的文献

1
The Effect of Glucagon-like-Peptide-1 Receptor Agonists on Diabetic Retinopathy Progression, Central Subfield Thickness, and Response to Intravitreal Injections.胰高血糖素样肽-1受体激动剂对糖尿病视网膜病变进展、中心子野厚度及玻璃体内注射反应的影响。
J Clin Med. 2024 Oct 21;13(20):6269. doi: 10.3390/jcm13206269.
2
Two-year Outcomes of Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration with "Observe before Treat-and-Extend" Method.“观察等待-治疗-再延长”方案下玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性的两年疗效观察。
Korean J Ophthalmol. 2024 Oct;38(5):380-391. doi: 10.3341/kjo.2024.0083. Epub 2024 Aug 20.

本文引用的文献

1
Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study.OCT引导下的渗出性年龄相关性黄斑变性再治疗是否需要散瞳眼底检查?一项前瞻性、随机、试点研究。
Clin Ophthalmol. 2021 Aug 12;15:3401-3417. doi: 10.2147/OPTH.S315554. eCollection 2021.
2
Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles.年龄相关性黄斑变性新生血管长期预后:治疗结果与主要风险等位基因的关系。
Br J Ophthalmol. 2022 Nov;106(11):1555-1560. doi: 10.1136/bjophthalmol-2021-319054. Epub 2021 Jun 2.
3
Factors affecting non-adherence to medical appointments among patients with hypertension at public health facilities in Punjab, India.
影响印度旁遮普邦公立卫生机构高血压患者不遵守医疗预约因素。
J Clin Hypertens (Greenwich). 2021 Apr;23(4):713-719. doi: 10.1111/jch.14142. Epub 2021 Jan 17.
4
Frequency of Rhegmatogenous Retinal Detachment after Intravitreal Therapy in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性患者玻璃体内治疗后孔源性视网膜脱离的频率。
Ophthalmol Retina. 2020 Oct;4(10):973-978. doi: 10.1016/j.oret.2020.03.028. Epub 2020 Apr 14.
5
Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahy-Guided Intravitreal Injections.消除视力和眼底散瞳检查可提高光相干断层扫描引导下玻璃体腔内注射的成本效率。
Am J Ophthalmol. 2020 Nov;219:222-230. doi: 10.1016/j.ajo.2020.06.028. Epub 2020 Jul 2.
6
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.玻璃体内注射阿柏西普按需治疗方案治疗渗出性年龄相关性黄斑变性的疗效和安全性:ALTAIR 随机对照研究的 52 周和 96 周结果。
Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3.
7
Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?OCT 引导下渗出型年龄相关性黄斑变性再治疗是否需要散瞳眼底检查?
Ophthalmol Retina. 2020 Feb;4(2):141-147. doi: 10.1016/j.oret.2019.09.006. Epub 2019 Sep 18.
8
Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study.新生血管性年龄相关性黄斑变性治疗并延长给药方案与每月给药方案的随机试验:TREX-AMD研究的2年结果
Ophthalmol Retina. 2017 Jul-Aug;1(4):314-321. doi: 10.1016/j.oret.2016.12.004. Epub 2017 Feb 2.
9
Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using "Treat and Extend" Regimen.采用“治疗与延长”方案玻璃体腔内注射抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性5年的疗效
Front Med (Lausanne). 2018 May 1;5:125. doi: 10.3389/fmed.2018.00125. eCollection 2018.
10
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations.2018年玻璃体内注射最新进展:欧洲视网膜专家共识推荐
Ophthalmologica. 2018;239(4):181-193. doi: 10.1159/000486145. Epub 2018 Feb 1.